Tectonic Therapeutic

Tectonic Therapeutic is a biotech startup co-founded by Andrew Kruse and Tim Springer of Harvard Medical School. The company is focused on the discovery and development of antibodies and other biologic drugs that target G-protein Coupled Receptors (GPCRs). GPCRs are a large class of proteins that play a key role in many biological processes and are the target of a large number of drugs. However, some GPCRs have been difficult to target with drugs, and Tectonic is working to change that.

The company's proprietary GEODe™ platform is designed to target these previously "undruggable" receptors, with the aim of developing new treatments for a wide range of patients with unmet medical needs. In other words, Tectonic is trying to find new ways to treat diseases that currently have no effective treatments.

Tectonic operates in the biotech market, serving clients in the healthcare and pharmaceutical industries. The company's business model is based on the research and development of new drugs, which it then aims to commercialize either by selling the drugs directly or by licensing them to larger pharmaceutical companies.

The company is led by a team of experienced executives and scientists, including President and CEO Alise Reicin, M.D., and Chief Scientific Officer Peter McNamara, Ph.D. The company's co-founder, Tim Springer, was recently awarded the 2022 Lasker Award, a prestigious recognition in the field of medical research.

Keywords: Biotech, Drug Discovery, G-protein Coupled Receptors, Undruggable Targets, GEODe™ Platform, Antibodies, Biologic Drugs, Healthcare, Pharmaceutical, Lasker Award.